Resource-Sparing Curative Treatment for Rectal Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a prospective, multicentre, randomized clinical trial comparing two different neo-adjuvant radiation-based strategies prior to intended surgery for locally advanced adenocarcinoma of the rectum.
This trial may establish the investigational therapy to be superior to, or at least not inferior to conventional treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Rectal Carcinoma |
Radiation: Radiotherapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Resource-Sparing Curative Treatment for Rectal Cancer |
- Overall Survival [ Time Frame: From commencement of radiation (day 1) to death or last follow-up up to 5 years. ] [ Designated as safety issue: No ]
- Biological Effect and Tumour Biology [ Time Frame: Prior to surgical decision in weeks 13-15 and 4 weeks after surgery ] [ Designated as safety issue: No ]
Maximum size of the tumor based on imaging and/or up to 3D measures reported by radiologists, comparing baseline and pre-surgical decision inverstigations
If definitive surgery is conducted:
- Proportion obtaining R0
- Proportion undergoing TME
- Status of the neurovascular and neural invasion(s)
- Nodal ratio
- Tumor sizes
CEA results
- Quality of Life [ Time Frame: From date of randomization till the end of follow-up (5 years) ] [ Designated as safety issue: No ]
- Health-related Economics [ Time Frame: From date of randomization till the end of follow-up (5 years) ] [ Designated as safety issue: No ]
Number of days in hospital
Number of surgical procedures
Number of days with stomas
Protocol required therapies, as actually administered
Adverse events that have significant cost implications (i.e. cost-drivers)
| Estimated Enrollment: | 350 |
| Study Start Date: | September 2009 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Arm A: Conventional Long Course Chemo-Radiation
Conventional long course chemo-radiation
|
Radiation: Radiotherapy
Conventional long course chemo-radiation:
|
|
Experimental: Arm B: Short Course Radiation Followed by Chemotherapy
Experimental short course radiation followed by chemotherapy.
|
Radiation: Radiotherapy
Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day
|
Detailed Description:
This phase III randomised clinical trial compares the outcome of two different neo-adjuvant radiation based treatments for locally advanced rectal carcinoma. This encompasses patients at risk for a positive circumfrential resection margin (CRM+) on baseline assessment imaging and pateints identified as being with a T-descriptor T4 at baseline assessment.
The arms compared are as follows:
- The investigational arm: short chemo-radiation course(25Gy in 5 daily fractions over 1 week) +/- surgery.
- The conventional arm: protracted chemo-radiation course (50Gy in 25 daily fractions over 5 weeks combined with chemotherapy)+/- surgery.
The outcomes include four domains: overall survival, biological effect, quality of life and health-related economics.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older
- Clinical (i.e. surgical determination) and/or diagnostic image findings consistent with c/uT4 or CRM+ (note that CRM+ must be established by MRI), primary rectal Adenocarcinoma (i.e. histology consistent with origin from rectal mucosa); these constitute LARC for the purpose of this protocol
- Treatment will be directed at the primary cancer, being clinically appropriate and given with an initial intent to cure the patient (this includes accepting up front that radiation and surgery are feasible; for surgery, this means that the patient has been determined fit for major surgery by an anaesthesiologist prior to the request for randomization)
- Performance status is sufficient to undertake the treatment in either arm (KPS>50%)
- Patient is accessible for required follow-up and data collection
- Radiation oncologist expects survival to exceed 6 months from date of diagnosis
- Patient provides informed consent
Exclusion Criteria:
- Recurrent rectal cancer
- Primary wholly in the sigmoid colon
- Considered to be arising in the anal canal
- Metastatic disease beyond the pelvis (by clinical assessment and/or diagnostic imaging)
- Contraindications to protocol RT or to protocol chemotherapy, such as one or more of the following:
- any prior RT to the pelvis; a solitary pelvic kidney within the intended radiation volume
- consideration by the most responsible radiation oncologist that the treatment volume is too large, or the amount of small bowel or other critical organs within the treatment volume is too much for safe treatment
- significantly abnormal laboratory tests such as impaired renal/liver function
- a haemoglobin that is < 8.0 (or 80, SI) and the patient is not transfused to exceed 8.0 (or 80, SI)
- on-going medications that are not compatible with protocol neo-adjuvant chemotherapy as described in this protocol
- Significant development issues (such as with age < 18 yr)
- Co-morbidity
- Psychiatric diagnosis
- Physical impairment
- Pregnancy or continuing breast-feeding, that precludes administration of protocol treatments, or that precludes data collection (such as likely to preclude follow-up visits or completing questionnaires)
Contacts and Locations| Contact: IAEA |
| Algeria | |
| Centre Anti-Cancer, Hopital Franz Fanon | Recruiting |
| Blida, Algeria, 09000 | |
| Contact: Boualga Kada +213 25 415985 kboualga2002@yahoo.fr | |
| Principal Investigator: Boualga Kada | |
| Brazil | |
| Hospital A.C. Camargo, Fundacao Antonio Prudente | Recruiting |
| Sao Paulo, Brazil, 01509-010 | |
| Contact: Maria Leticia Gobo Silva +551132729613 mlgobo@yahoo.fr | |
| Principal Investigator: Maria Leticia Gobo Silva | |
| Canada, Ontario | |
| Credit Valley Hospital | Recruiting |
| Mississauga, Ontario, Canada, L5M 2N1 | |
| Contact: Jidong Lian ombudsman@cvh.on.ca | |
| Principal Investigator: Jidong Lian | |
| Colombia | |
| Instituto Nacional de Cancerologia, Minesterio de Salud | Recruiting |
| Bogota D.C., Colombia | |
| Contact: Rosalba Ospinp Pena 005713341997 rospino@cancer.gov.co | |
| Principal Investigator: Rosalba Ospino Pena | |
| Croatia | |
| Department of Oncology and Nuclear Medicine, University Hospital Sestre Milosrdnice | Recruiting |
| Zagreb, Croatia, 10000 | |
| Contact: Ana Frobe +38513787468 afrobe@irb.hr | |
| Principal Investigator: Blanka Jaksic | |
| Cuba | |
| Ministerio de Cienca, Tecnologia y Medio Ambiente (CITMA) | Recruiting |
| La Habana, Cuba | |
| Contact: Maria Lourdes Pernez Pena +5378316040 soconcol@infomed.sld.cu | |
| Principal Investigator: Aixa Ulloa Balmaseda | |
| India | |
| Department of Radiation Oncology, V.N. Cancer Center, GKNM Hospital | Recruiting |
| Coimbatore, India, Tamil Nadu 641 037 | |
| Contact: Nagarajan Murugaiyan +9104222216715 mnagarajan@gknmh.org | |
| Contact mnr81@yahoo.com | |
| Principal Investigator: Nagarajan Viswanathan | |
| Department of Radiation Oncology, Tata Memorial Hospital | Recruiting |
| Mumbai, India, Maharashtra 400 012 | |
| Contact: Reena Engineer +912224177163 reena_engineer@rediffmail.com | |
| Contact +912224177000 | |
| Principal Investigator: Shyam Kishore Shrivastava | |
| Indonesia | |
| Department of Radiotherapy, Dr. Cipto Mangunkusuma National General Hospital, University of Indonesia | Recruiting |
| Jakarta, Indonesia, 10430 | |
| Contact: Sri Mutya Sekarutami +62213921155 smutya12@yahoo.com | |
| Principal Investigator: Sri Mutya Sekarutami | |
| Italy | |
| Instituto di Radiologia, Universita Cattolica del Sacro Cuore | Recruiting |
| Roma, Italy, 00168 | |
| Contact: Vincenzo Valentini +390630154376 vvalentini.it@email.it | |
| Principal Investigator: Vincenzo Valentini | |
| Slovakia | |
| National Cancer Institute | Recruiting |
| Bratislava, Slovakia, 833 10 | |
| Contact: Margita Pobijakova +421259378579 margita.pobijakova@nou.sk | |
| Principal Investigator: Margita Pobijakova | |
| South Africa | |
| University of Cape Town | Recruiting |
| Cape Town, South Africa, 7701 | |
| Contact: Barbara Robertson Barbara.robertson@uct.ac.za | |
| Principal Investigator: Barbara Robertson | |
| Principal Investigator: | Eduardo Rosenblatt | International Atomic Energy Agency |
More Information
Additional Information:
Publications:
| Responsible Party: | International Atomic Energy Agency |
| ClinicalTrials.gov Identifier: | NCT01459328 History of Changes |
| Other Study ID Numbers: | E33034 |
| Study First Received: | October 10, 2011 |
| Last Updated: | October 24, 2011 |
| Health Authority: | United Nations: International Atomic Energy Agency |
Keywords provided by International Atomic Energy Agency:
|
rectal carcinoma long course chemo-radiation short course chemo-rdiation Locally Advanced Rectal Carcinoma |
Additional relevant MeSH terms:
|
Carcinoma Rectal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Colorectal Neoplasms Intestinal Neoplasms |
Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases |
ClinicalTrials.gov processed this record on May 23, 2013